The relevance of an in vitro assay
is often questioned because the nature and range of response of the system is unlikely to resemble fully that of the in vivo system.
The matching ready-to-use and validated SYBR(R) Green-based qRT-PCR assay
portfolio is supplemented by QIAGEN's QuantiTect(R) Primer Assays
for real-time RT-PCR providing specificity and sensitivity comparable to sequence-specific probe-based assays
Blood samples from the Hong Kong cohort of patients were tested for neutralizing antibodies to the SARS-CoV S protein by using the pseudotype neutralization assay
Most protein assays
are based on colorimetric methods.
test a chemical's ability to induce DNA damage.
Rather than attempting comprehensive coverage of all assay
development technologies, the book introduces the most widely used assay
development technologies and illustrates the art of assay
development through a few commonly encountered biological targets in assay
The consumables formed the largest product segment of the total cell-based assays
market in 2013, which includes assay
kits and reagents, microplates and cell lines.
Cell-based Assays Market by Product [Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services], Application (Drug Discovery, ADMET), End-user (Pharmaceutical, CRO) - Global Forecast to 2018
leading provider of drug discovery, life science research and analytical solutions, has announced that its DELFIA(R) Xpress first trimester prenatal screening assays
have been approved by the Fetal Medicine Foundation (FMF), London, UK.
Stimulation was also performed on whole blood samples; however, the assay
had reduced sensitivity.
For this report, we examined the estrogenic activities of styrene oligomers in the presence or absence of a liver microsomal metabolic system using a yeast estrogen screening (YES) assay
and an estrogen-responsive element (ERE)-luciferase reporter assay
in the estrogen-responsive human breast cancer cell line MCF-7.
We calculated inhibitions as described above and defined the working range of the assay
as the concentration of brevetoxins inhibiting between 20% and 80% of the signal.
DiscoveRx Corporation today announced that it has expanded its cell-based PathHunter(TM) [eth]-Arrestin assays
to include 45 validated cell products, each expressing a different Gi, Gs or Gq -coupled receptor.